'I'll be a hero in three years'

By This Is Money
Updated: 00:00 BST, 4 April 2004

?

NO ONE could 告発する／非難する ジーンズ-Pierre Garnier of selling himself short. From his 抱擁する £6m-a-year 支払う／賃金 一括 to his 役割 in 'transforming' the world of 研究 and 開発, the 長，指導者 (n)役員／(a)執行力のある of 麻薬s 巨大（な） GlaxoSmithKline is 堅固に cast as the 星／主役にする of his show.

This 56-year-old French- born '国民 of the world' is a 熱烈な 支持する for his own 'daring' and 'bold' 率先 to transform 研究 and 開発 at GSK, breaking it into small 衛星s. The 目的（とする） is to mimic the dynamism of biotech companies and wring more 生産性 out of its 年次の spending of £2.2bn.

'Remember,' he says, 'no other company has done this. It is pathetic that we have to be the one to 直す／買収する，八百長をする the problem, that for the first time in 25 years, the 製薬の 産業 is not 生産力のある.

'Has it been rough? Yes, but to 確実にする we 後継する in transforming 研究 and 開発 生産性 - that is the most important thing. The company is at 火刑／賭ける here.'

His self-belief is unstinting and he has no 疑問 that he is 価値（がある） what he is paid - and then some.

Garnier, who is married with three grown-up daughters, has his home in Philadelphia. He lives the American Dream and has caught the can-do ethos of big 商売／仕事 over there. But he is a コンビナート／複合体 character who would appear to be a bringer of 強調する／ストレス rather than a 苦しんでいる人. He cheerfully 収容する／認めるs: 'Zen-like, I am not. It is not my temperament and I have made peace with myself there.

'Obsessive? Yes, yes, I am obsessive and impatient. But anxious does not 述べる me. I have no trouble making difficult 決定／判定勝ち（する）s. I do not agonise too much - just ask around. I sleep 井戸／弁護士席 at night.'

It is not the sleep of exhaustion, にもかかわらず his gruelling travels, admittedly in the 高級な of GSK's 私的な jet. Two weeks ago he was in Dubai and Cairo; last week it was London, this week America.

But Garnier （人命などを）奪う，主張するs it is not lust for money that 運動s him, just success and status. Money is 簡単に the 得点する／非難する／２０. His now 悪名高い 追跡 of higher 支払う／賃金 and a historic £12m golden パラシュート（で降下する） was thrown out by 株主s last year, but it was 'the 得点する／非難する／２０' he believed he deserved.

He has steered GSK through the loss of 特許s on three of its blockbuster 麻薬s: the 抗生物質 Augmentin and anti-depressants Seroxat and Wellbutrin.

These three 麻薬s 生成するd $4bn 年次の sales in America, where 60% of the group's 利益（をあげる）s are made.

'Those sales have disappeared 事実上 夜通し,' says Garnier, 'yet still we have managed 収入s per 株 growth of an 普通の／平均（する） 8% over the past three very rough years.' And he 主張するs: 'I'll be a hero in two or three years when our four big bets on 分子s, now in 裁判，公判s, will be とじ込み／提出するd for regulatory 是認.'

同様に as problems at GSK, Garnier has 直面するd 問題／発行するs that have 疫病／悩ますd the 産業 - price, under-開発 of 製品s, 特許s and politics.

'Listen, I really can't complain,' he says. 'I like my 職業. Yes, I was served a couple of ジュースs, not a couple of エースs, but that's 承認する.'

支払う／賃金 is one 問題／発行する Garnier can hardly complain about, にもかかわらず last year's 株主 反乱. The remuneration 委員会 took the 見解（をとる） that 'superior results' were produced after taking account of 'factors outside the 支配（する）／統制する of 管理／経営', 顕著に 交流 率 change and loss of 重要な 麻薬s to generic 競争 in the USA.

Losing one lucrative 特許 might be bad luck, but losing three seems to be careless. And 交流 率 changes can be controlled by hedging. With a Gallic shrug and a warm, wide smile that takes 20 years off him, Garnier sidesteps the 問題／発行するs.

But if he 裁判官s a question to be 'chasing a phantom' and/or 'not an 問題／発行する', charm is likely to 産する／生じる to a raised 発言する／表明する. On 'factors outside the 支配（する）／統制する of 管理／経営', he replies with 熟考する／考慮するd patience: 'Foreign 交流 is certainly outside our 支配（する）／統制する.' As for loss of 特許s, only Augmentin was not foreseen and （機の）カム as a shock.

The company's sickly 株 price 反映するs 深い 疑問s about GSK's growth prospects. But Garnier remains irrepressibly 楽観的な. So what is he on?

He laughs. 'I do not need to take anything. I am fortunate to be in very good health. And you have to be 井戸／弁護士席 in your 長，率いる. You have to enjoy not the 目的地, but the 旅行.'

Sorry, it's only £6m

IN an 前例のない 反乱 last year, 株主s 投票（する）d against GlaxoSmithKline's remuneration 報告（する）／憶測 after it 現れるd that Garnier was in line for £12m if he lost his 職業.

A chastened Glaxo 協議するd 投資家s and agreed to 削減（する） Garnier's 契約 from two years to 12 months, halving the size of any 可能性のある 支払う／賃金-off.

That did not stop Garnier's 支払う／賃金 last year rising to £2.8m, up from £2.45min 2002. He also made £2.7m from cashing-in 株 選択s. In February, Garnier netted a その上の £3.6m from 選択 伸び（る）s.